Trial NCT05060432 (View at ClinicalTrials.gov)

This trial evaluates EOS-448 in combination with pembrolizumab, and also in combination with Inupadenant, in patients with advanced solid tumors. The purpose of this trial is to assess the safety and tolerability of EOS-448 when used in combination with each of these drugs, to determine the recommended Phase 2 dose, and to further explore the anti-tumor activity of each combination.

Trial NCT03739710 (View at ClinicalTrials.gov)

This trial evaluates the clinical activity of EOS-448 in combination with dostarlimab in patients with relapsed/refractory advanced non-small cell lung cancer. The purpose of this trial is to assess the drug’s safety, tolerability, and anti-tumor activity compared to other treatments.

Trial NCT04335253 (View at ClinicalTrials.gov)

This trial evaluates EOS-448 as a single agent therapy in patients with advanced solid tumors. The purpose of this trial is to evaluate the safety of the drug, measure the amount of drug in the body after dosing, measure the effects of the drug on the body, and evaluate the effect of the drug on the tumor.

Trial NCT06547957 (View at ClinicalTrials.gov)

This trial evaluates EOS-984 as a single agent therapy in patients with advanced solid tumors. The purpose of this trial is to evaluate the safety of the drug, measure the amount of drug in the body after dosing, measure the effects of the drug on the body, and evaluate the effect of the drug on the tumor.